MA33606B1 - Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 - Google Patents

Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2

Info

Publication number
MA33606B1
MA33606B1 MA34719A MA34719A MA33606B1 MA 33606 B1 MA33606 B1 MA 33606B1 MA 34719 A MA34719 A MA 34719A MA 34719 A MA34719 A MA 34719A MA 33606 B1 MA33606 B1 MA 33606B1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
pyrimidine derivatives
protein inhibitors
compounds
relates
Prior art date
Application number
MA34719A
Other languages
Arabic (ar)
English (en)
Inventor
Heinz Stadtmueller
Ioannis Sapountzis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43048878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33606(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33606B1 publication Critical patent/MA33606B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne des composés de formule générale (1a) et (1b), où les groupes r1 à r5, a, q, m, n, p et q sont tels que définis dans la revendication 1, composés qui sont des inhibiteurs de fak/ptk2 et qui peuvent ainsi être utilisés dans le cadre du traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale. L'invention concerne également l'utilisation desdits composés en tant que médicaments.
MA34719A 2009-10-02 2012-03-26 Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 MA33606B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172026 2009-10-02
EP10172460 2010-08-11
PCT/EP2010/064628 WO2011039344A1 (fr) 2009-10-02 2010-10-01 Dérivés de pyrimidine utilisables en tant qu'inhibiteurs de la protéine qu'est la tyrosine kinase 2

Publications (1)

Publication Number Publication Date
MA33606B1 true MA33606B1 (fr) 2012-09-01

Family

ID=43048878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34719A MA33606B1 (fr) 2009-10-02 2012-03-26 Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2

Country Status (24)

Country Link
US (1) US8466155B2 (fr)
EP (1) EP2483249B1 (fr)
JP (1) JP5702390B2 (fr)
KR (1) KR20120092617A (fr)
CN (1) CN102695700A (fr)
AP (1) AP2012006166A0 (fr)
AR (1) AR078513A1 (fr)
AU (1) AU2010302648A1 (fr)
BR (1) BR112012007300A2 (fr)
CA (1) CA2775418A1 (fr)
CL (1) CL2012000825A1 (fr)
EA (1) EA201200552A1 (fr)
EC (1) ECSP12011830A (fr)
IL (1) IL218543A0 (fr)
IN (1) IN2012DN02714A (fr)
MA (1) MA33606B1 (fr)
MX (1) MX2012003101A (fr)
NZ (1) NZ598614A (fr)
PE (1) PE20121431A1 (fr)
TN (1) TN2012000142A1 (fr)
TW (1) TW201124386A (fr)
UY (1) UY32916A (fr)
WO (1) WO2011039344A1 (fr)
ZA (1) ZA201201703B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
EP2675794B1 (fr) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Inhibiteurs sélectifs de fak
CA2827171C (fr) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Inhibiteurs de fak
EP2788378A4 (fr) * 2011-12-09 2015-09-09 Oncomed Pharm Inc Thérapie d'association pour le traitement du cancer
EP2832734A4 (fr) * 2012-03-28 2015-08-26 Takeda Pharmaceutical Composé hétérocyclique
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
WO2014190207A1 (fr) * 2013-05-22 2014-11-27 The Regents Of The University Of California Inhibiteurs d'aurora kinase
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (fr) 2015-02-20 2021-08-04 Incyte Corporation Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3099116A1 (fr) 2018-05-04 2019-11-07 Incyte Corporation Sels d'un inhibiteur de fgfr
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3162010A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Derives d'un inhibiteur de fgfr
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
RS94703A (en) * 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk inhibiting pyrimidines, production thereof and their use as medicaments
EP2090571B1 (fr) 2001-10-17 2012-05-16 Boehringer Ingelheim Pharma GmbH & Co. KG Derivés pyrimidine, agent pharamceutique contenant ces composés, utilisation et procédé de fabrication de ces composés
AU2003212282A1 (en) * 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
CA2566531A1 (fr) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Composes pyrimidinediamines a substitution cycloalkyle et leurs utilisations
EP1794134A1 (fr) * 2004-09-29 2007-06-13 Bayer Schering Pharma Aktiengesellschaft 2-anilinopyrimidine substituee utilisee en tant que kinase a cycle cellulaire ou recepteur de la tyrosine kinase, leur production et leur utilisation en tant que medicament
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008077885A2 (fr) * 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh Nouveaux composés
WO2008128231A1 (fr) 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Dérivés de pyrimidine
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
AR074209A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法

Also Published As

Publication number Publication date
IL218543A0 (en) 2012-05-31
ECSP12011830A (es) 2012-06-29
US20110237598A1 (en) 2011-09-29
NZ598614A (en) 2013-08-30
KR20120092617A (ko) 2012-08-21
AU2010302648A1 (en) 2012-04-05
EP2483249B1 (fr) 2015-12-23
US8466155B2 (en) 2013-06-18
AP2012006166A0 (en) 2012-04-30
AR078513A1 (es) 2011-11-16
CA2775418A1 (fr) 2011-04-07
UY32916A (es) 2011-04-29
ZA201201703B (en) 2014-05-28
EA201200552A1 (ru) 2013-03-29
MX2012003101A (es) 2012-04-11
TW201124386A (en) 2011-07-16
CN102695700A (zh) 2012-09-26
CL2012000825A1 (es) 2012-08-24
JP5702390B2 (ja) 2015-04-15
WO2011039344A1 (fr) 2011-04-07
JP2013506636A (ja) 2013-02-28
BR112012007300A2 (pt) 2017-11-07
PE20121431A1 (es) 2012-11-10
TN2012000142A1 (en) 2013-09-19
IN2012DN02714A (fr) 2015-09-11
EP2483249A1 (fr) 2012-08-08

Similar Documents

Publication Publication Date Title
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA31167B1 (fr) Inhibiteurs de l'activite de akt
TN2009000551A1 (fr) Nouveaux composes chimiques
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TN2015000168A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
DE602005024004D1 (de) Als beta-sekretase (bace)-hemmer nützliche 2-amino-chinazolinderivate
MA44674A (fr) Inhibiteurs de bromodomaine
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
TW200600505A (en) Compounds and compositions as ppar modulators
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200802054A1 (ru) Ингибиторы фермента
EA200700909A1 (ru) Азаиндолкарбоксамиды
MA38648B1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
MA29723B1 (fr) Composes
MA35895B1 (fr) Inhibiteurs d'iap